Madrigal Pharmaceuticals, Inc. MDGL Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $232.19M+23.1% | $203.78M+94.0% | $300.69M+26.5% | $191.19M-61.7% | $188.65M-69.7% | ||
| $585.74M-11.2% | $784.87M-5.0% | $814.06M+6.3% | $610.83M+8.5% | $659.42M+51.1% | ||
| $5.16M+3.1% | $5.09M+1.8% | $5M0.0% | $5M0.0% | $5M+317% | ||
| $187.36M+205% | $134.48M+150% | $113.29M+272% | $79.23M+1,048% | $61.43M— | ||
| $112.07M+103% | $74.84M+120% | $69.32M+695% | $63.5M+798% | $55.24M+6,369% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $106.26M+108% | $67.63M+129% | $62.9M+1,067% | $57.91M+911% | $50.97M+21,589% | ||
| $5.81M+36.0% | $7.21M+58.9% | $6.41M+92.8% | $5.59M+316% | $4.27M+590% | ||
| $64.96M+179% | $47.8M+247% | $49.33M+136% | $58.6M+292% | $23.24M+65.6% | ||
| $1.18B+19.7% | $1.25B+20.6% | $1.35B+26.6% | $1B-8.1% | $987.98M-8.0% | ||
| $8.04M+323% | $1.5M-31.6% | $2.91M+28.4% | $1.62M-4.7% | $1.9M+9.1% | ||
| $6.2M+194% | $4.94M+106% | $5.39M+114% | $5.86M+303% | $2.11M+33.0% | ||
| $7.28M+57.0% | $7.38M+56.1% | $7.48M+55.2% | $4.55M-7.4% | $4.64M-7.2% | ||
| $23.5M— | $0— | —— | —— | —— | ||
| $1.23B+23.1% | $1.26B+20.9% | $1.36B+26.9% | $1.02B-7.7% | $996.63M-7.9% | ||
| $60.8M+44.6% | $48.88M+12.1% | $44.94M-2.2% | $37.98M+322% | $42.06M+95.4% | ||
| $34.33M+87.9% | $69.21M-44.5% | $51.11M+72.2% | $27.69M+29.8% | $18.27M+7.8% | ||
| $29.98M+158% | —— | $31.06M+155% | $11.6M-9.1% | $11.6M-9.1% | ||
| $1.7M+67.0% | $1.02M+3.6% | $1.08M+23.3% | $1.05M+88.3% | $1.02M+87.5% | ||
| $128.89M— | —— | $148.98M— | $22.28M— | —— | ||
| $338.26M+102% | $310.29M+83.3% | $391.41M+120% | $196.5M+57.0% | $167.24M+46.3% | ||
| $340.33M+188% | $339.88M+189% | $339.75M+190% | $118.38M+1.5% | $118.01M+1.6% | ||
| $5.28M+605% | $6.73M+561% | $5.57M+373% | $4.52M+403% | $750K-28.2% | ||
| $345.61M+191% | $346.61M+192% | $345.32M+192% | $122.9M+4.6% | $118.76M+1.3% | ||
| $683.87M+139% | $656.9M+128% | $736.73M+149% | $319.4M+31.6% | $285.99M+23.5% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| 200M0.0% | 200M+9,999,900% | 200M0.0% | 200M0.0% | 200M0.0% | ||
| $2.73B+5.5% | $2.69B+5.3% | $2.66B+5.5% | $2.61B+4.8% | $2.59B+10.7% | ||
| -$2.18B-16.5% | -$2.09B-16.0% | -$2.03B-16.6% | -$1.92B-17.2% | -$1.88B-26.4% | ||
| $1.08M+178% | $873K+86.5% | $1.07M-16.0% | $1.11M+402% | $389K+326% | ||
| $543.45M-23.5% | $602.69M-20.1% | $625.73M-19.5% | $695.98M-18.8% | $710.64M-16.5% | ||
| $1.23B+23.1% | $1.26B+20.9% | $1.36B+26.9% | $1.02B-7.7% | $996.63M-7.9% | ||
| $0— | $0— | —— | —— | —— | ||
| $0— | $0— | —— | —— | —— | ||
| $585.74M-11.2% | $784.87M-5.0% | $814.06M+6.3% | $610.83M+8.5% | $659.42M+51.1% | ||
| $5.81M+36.0% | $7.21M+58.9% | $6.41M+92.8% | $5.59M+316% | $4.27M+590% | ||
| $23.5M— | $0— | —— | —— | —— | ||
| $6.2M+194% | $4.94M+106% | $5.39M+114% | $5.86M+303% | $2.11M+33.0% | ||
| $7.28M+57.0% | $7.38M+56.1% | $7.48M+55.2% | $4.55M-7.4% | $4.64M-7.2% | ||
| $6.2M+194% | $4.94M+106% | $5.39M+114% | $5.86M+303% | $2.11M+33.0% | ||
| $23.5M— | $0— | —— | —— | —— | ||
| $6.2M+194% | $4.94M+106% | $5.39M+114% | $5.86M+303% | $2.11M+33.0% | ||
| $23.5M— | $0— | —— | —— | —— | ||
| $34.33M+87.9% | $69.21M+98.0% | $51.11M+72.2% | $27.69M+29.8% | $18.27M+7.8% | ||
| $275.76M+122% | $260.39M+109% | $345.38M+164% | $157.48M+36.2% | $124.17M+34.6% | ||
| $275.76M+122% | $260.39M+109% | $345.38M+164% | $157.48M+36.2% | $124.17M+34.6% | ||
| $34.33M+87.9% | $69.21M+98.0% | $51.11M+72.2% | $27.69M+29.8% | $18.27M+7.8% | ||
| $22.59M+158% | —— | $7.83M+155% | $5.82M-9.1% | $8.74M-9.1% | ||
| $29.98M-76.2% | —— | $31.14M-60.7% | $126.02M+58.3% | $126.02M+58.3% | ||
| $9.67M+207% | —— | $10.25M+152% | $2.78M-38.9% | $3.15M-37.3% | ||
| $377.3M+187% | $347.63M+191% | $377.46M+187% | $135.55M+3.6% | $131.37M+0.7% | ||
| $478.89M+227% | —— | $498.98M+238% | $143.43M-5.7% | $146.36M-5.8% | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 23M+3.8% | 22.8M+3.8% | 22.7M+4.1% | 22.2M+11.8% | 22.2M+11.6% | ||
| 5M0.0% | 5M0.0% | 5M0.0% | 5M0.0% | 5M0.0% | ||
| 2.4M0.0% | 2.4M0.0% | 2.4M0.0% | 2.4M0.0% | 2.4M0.0% | ||
| 2.4M0.0% | 2.4M0.0% | 2.4M0.0% | 2.4M0.0% | 2.4M0.0% | ||
| $2.73B+5.5% | $2.69B+5.3% | $2.66B+5.5% | $2.61B+4.8% | $2.59B+10.7% | ||
| $2K0.0% | $2K0.0% | $2K0.0% | $2K0.0% | $2K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| 716.1K-37.8% | —— | 789.4K-39.2% | 1.2M-10.4% | 1.2M-37.8% | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 1M-33.3% | 979.9K-35.9% | 1.1M-35.9% | 1.5M-13.6% | 1.5M-37.9% | ||
| $377.1M+55.4% | —— | $243.4M+75.0% | $247.4M+65.9% | $242.7M+36.9% | ||
| $155K-64.4% | $879K+40.6% | $638K-51.1% | $270K+5,300% | $435K+663% | ||
| $401K+414% | $20K-87.3% | $181K+448% | $101K-72.9% | $78K-65.9% | ||
| $189.98+72.6% | $155.25+65.9% | $146.17+54.5% | $113.86+21.4% | $110.04+24.8% | ||
| $36.86M— | $26.91M— | —— | —— | —— | ||
| $46.83M— | $40.03M— | —— | —— | —— | ||
| $0— | $0— | —— | —— | —— | ||
| $401K+414% | $20K-87.3% | $181K+448% | $101K-72.9% | $78K-65.9% | ||
| $155K-64.4% | $879K+40.6% | $638K-51.1% | $270K+5,300% | $435K+663% | ||
| $818.17M— | $987.79M— | —— | —— | —— | ||
| $817.93M— | $988.65M— | —— | —— | —— | ||
| 2.3M— | —— | —— | —— | —— | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $00.0% | ||
| $200M0.0% | $200M0.0% | $200M0.0% | $200M0.0% | $200M0.0% | ||
| $23.04M+3.8% | $22.84M+3.8% | $22.7M+4.1% | $22.22M+11.8% | $22.19M+11.6% | ||
| $23.04M+3.8% | $22.84M+3.8% | $22.7M+4.1% | $22.22M+11.8% | $22.19M+11.6% | ||
| $478.89M+227% | —— | $498.98M+238% | $143.43M-5.7% | $146.36M-5.8% | ||
| $9.67M+207% | —— | $10.25M+152% | $2.78M-38.9% | $3.15M-37.3% | ||
| $377.1M+55.4% | —— | $243.4M+75.0% | $247.4M+65.9% | $242.7M+36.9% | ||
| $143.56M+279% | $99.34M+284% | $89.68M— | $52.34M— | $37.86M— | ||
| $30.07M-76.1% | —— | $31.06M-60.8% | $126.02M+58.3% | $126.02M+58.3% | ||
| $29.98M— | —— | $31.14M— | —— | —— | ||
| $366.27M— | —— | $31.06M— | —— | —— | ||
| $29.98M+158% | —— | $31.06M+155% | $11.6M-9.1% | $11.6M-9.1% | ||
| $22.59M+158% | —— | $7.83M+155% | $5.82M-9.1% | $8.74M-9.1% | ||
| —— | —— | —— | —— | —— | ||
| $36.99M+182% | $33.74M+313% | $20.94M+207% | $10.97M+114% | $13.11M+224% | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $00.0% | ||
| $5M0.0% | $5M0.0% | $5M0.0% | $5M0.0% | $5M0.0% | ||
| $2.37M0.0% | $2.37M0.0% | $2.37M0.0% | $2.37M0.0% | $2.37M0.0% | ||
| $2.37M0.0% | $2.37M0.0% | $2.37M0.0% | $2.37M0.0% | $2.37M0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $222.9M+150% | —— | $187.6M— | $71.2M— | $89.1M— | ||
| $120.75M— | $90.5M— | —— | —— | —— | ||
| 4— | —— | —— | —— | —— | ||
| 4— | —— | —— | —— | —— | ||
| $716.13K-37.8% | —— | $789.36K-39.2% | $1.19M-10.4% | $1.15M-37.8% | ||
| $1.02M-33.3% | $979.86K-35.9% | $1.09M-35.9% | $1.53M-13.6% | $1.53M-37.9% | ||
| $189.98+72.6% | $155.25+65.9% | $146.17+54.5% | $113.86+21.4% | $110.04+24.8% | ||
| $126.5+61.3% | —— | $107.68+37.3% | $81.2+2.6% | $78.44+3.9% | ||
| $9.9M— | —— | —— | —— | —— | ||
| $222.9M+150% | —— | $187.6M— | $71.2M— | $89.1M— | ||
| $22.59M+158% | —— | $7.83M+155% | $5.82M-9.1% | $8.74M-9.1% | ||
| $9.9M— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Madrigal Pharmaceuticals, Inc.'s total assets?
- Madrigal Pharmaceuticals, Inc. (MDGL) holds $1.2B in total assets, up 23.2% year over year.
- How much debt does Madrigal Pharmaceuticals, Inc. have?
- Madrigal Pharmaceuticals, Inc. carries $377.3M in total debt against $543.5M of shareholders' equity, a debt-to-equity ratio of 0.69.
- How much cash does Madrigal Pharmaceuticals, Inc. have?
- Madrigal Pharmaceuticals, Inc. holds $232.2M in cash and equivalents.
- Can Madrigal Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 3.50 — current assets exceed current liabilities.
- Where does Madrigal Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
